According to a new study, the chances of dying or being hospitalized following COVID-19 infection in individuals with psychiatric disorders were found to be twice as high in comparison to persons without mental disorders. This study, initiated by the Immuno-NeuroPsychiatry Network of the European College of Neuropsychopharmacology, was published in the peer-reviewed journal 'Lancet Psychiatry'.
In another study published in JAMA Network, schizophrenia spectrum, mood, or anxiety disorders are associated with increased risk of mortality in patients with coronavirus disease.
The study also found ICU admission rates were not affected. The research compiled data from 33 studies from 22 countries, comprising 1,469,731 patients with COVID-19, of whom 43,938 had mental disorders. 23 studies were included in a random-effects meta-analysis of crude and adjusted odds ratios for COVID-19 related mortality, hospitalization, and ICU admission in individuals with comorbid pre-existent mental disorders, investigating different diagnostic groups and classes of psychiatric drugs. Individuals with psychotic disorders and mood disorders, as well as patients receiving treatment with antipsychotics or anxiolytics (anxiety-reducing drugs) appeared as the most vulnerable groups for COVID-19-associated mortality.
Patients with substance use disorders were also at increased risk for hospitalization following COVID-19. The authors of the paper called for national and international health authorities to take concerted action by offering priority vaccination to patients with severe mental illness, intellectual disability, and substance use disorders, and highlight the urgency of actions to counteract possible reduced access to care.
Corresponding author, Dr. Livia De Picker, from the University Psychiatric Hospital Campus Duffel, Belgium, said, "Together with many colleagues from national and international psychiatric associations, we have been advocating for priority SARS-CoV-2 vaccination of patients with severe mental illness. However, it quickly became apparent that a lack of high-quality evidence on the mortality and hospitalization risks of patients with mental disorders was blocking implementation of our recommendations by healthcare policymakers."
"In several countries, pleas to change the vaccination strategy were discarded by national health authorities with the argument that the current scientific evidence did not distinguish particular groups of psychiatric patients who have a very high risk for severe COVID-19, hospitalizations, ICU admittance, and death due to COVID-19.
This paper offers precisely this and shows that pre-existing mental disorders, in particular, psychotic and mood disorders, and exposure to antipsychotics and anxiety-reducing drugs are associated with COVID-19 mortality. With this new evidence, not taking action is no longer an option," added De Picker. De Picker further said, "Importantly, our data revealed a striking contrast in patients with severe mental illness. Patients with psychotic disorders in particular were affected by the highest mortality risk but did not have an increased risk of hospital admission.
We know these patients face important barriers to physical healthcare, and our results suggest reduced access to care could have contributed to the increased mortality seen in this group." "Public health authorities need to take targeted action to ensure maximum vaccination uptake for all groups of at-risk patients identified in this study. Close monitoring and adequate hospital referral in patients with psychiatric disorders who develop COVID-19 are needed to counteract possible reduced access to care," noted De Picker.
Author and director of the ImmunoNeuroPsychiatry Network, Professor Marion Leboyer (University of Paris Est Creteil, France) said, "This high-quality study was created through the concerted efforts of many international colleagues working together. Further work is needed to determine the causes of the poor COVID-19 outcomes in psychiatric patients, which might reflect biological processes, such as immune-inflammatory alterations related to the psychiatric disorders." Leboyer added, "In particular the impact of psychopharmacological treatments requires further study.
We found that exposure to antipsychotic and anxiolytic drug treatments initiated before contracting COVID-19 was associated with severe COVID-19 outcomes. Antipsychotics might increase cardiovascular and thromboembolic risks, interfere with an adequate immune response, and cause interactions with drugs used to treat COVID-19." "Benzodiazepines are associated with respiratory risk and are known to be associated with all-cause mortality. By contrast, some antidepressants were recently shown to have protective effects. In addition, social and lifestyle factors such as diet, physical inactivity, social isolation, high alcohol, and tobacco use, and sleep disturbances, and a higher prevalence of somatic comorbidities might also have detrimental effects on COVID-19 prognosis," concluded Leboyer.
(ANI)
